Skip to main content
Top
Published in: European Journal of Clinical Microbiology & Infectious Diseases 3/2023

21-01-2023 | Imipenem | Brief Report

Activity of ceftolozane/tazobactam and imipenem/relebactam against clinical gram-negative isolates from Czech Republic, Hungary, and Poland—SMART 2017–2020

Authors: Sibylle H. Lob, Stephen P. Hawser, Fakhar Siddiqui, Irina Alekseeva, C. Andrew DeRyke, Katherine Young, Mary R. Motyl, Daniel F. Sahm

Published in: European Journal of Clinical Microbiology & Infectious Diseases | Issue 3/2023

Login to get access

Abstract

Antimicrobial susceptibility was determined for clinical gram-negative isolates from Czech Republic, Hungary, and Poland, where published data for ceftolozane/tazobactam (C/T) and imipenem/relebactam (IMI/REL) is scarce. C/T was active against 94.3% of Enterobacterales, 10–18% higher than the tested cephalosporins and piperacillin/tazobactam. IMI/REL was the most active tested agent against non-Morganellaceae Enterobacterales (99.7% susceptible). C/T was the most active among all studied agents except colistin against Pseudomonas aeruginosa (96.0% susceptible); susceptibility to IMI/REL was 90.7%. C/T maintained activity against 73.7–85.3% of β-lactam-resistant or multidrug-resistant P. aeruginosa subsets. C/T and IMI/REL could represent important treatment options for patients from these countries.
Literature
2.
go back to reference Clinical and Laboratory Standards Institute (2018) Methods for dilution antimicrobial susceptibility tests for bacteria that grow aerobically, 11th ed, M07-A11. Approved standard. Clinical and Laboratory Standards Institute, Wayne, PA Clinical and Laboratory Standards Institute (2018) Methods for dilution antimicrobial susceptibility tests for bacteria that grow aerobically, 11th ed, M07-A11. Approved standard. Clinical and Laboratory Standards Institute, Wayne, PA
4.
go back to reference Clinical and Laboratory Standards Institute (2021) M100 performance standards for antimicrobial susceptibility testing, 31st ed. Clinical and Laboratory Standards Institute, Wayne, PA Clinical and Laboratory Standards Institute (2021) M100 performance standards for antimicrobial susceptibility testing, 31st ed. Clinical and Laboratory Standards Institute, Wayne, PA
5.
go back to reference Lob SH, Biedenbach DJ, Badal RE, Kazmierczak KM, Sahm DF (2015) Antimicrobial resistance and resistance mechanisms of Enterobacteriaceae in ICU and non-ICU wards in Europe and North America: SMART 2011–2013. J Glob Antimicrob Resist 3:190–197CrossRef Lob SH, Biedenbach DJ, Badal RE, Kazmierczak KM, Sahm DF (2015) Antimicrobial resistance and resistance mechanisms of Enterobacteriaceae in ICU and non-ICU wards in Europe and North America: SMART 2011–2013. J Glob Antimicrob Resist 3:190–197CrossRef
6.
go back to reference Nichols WW, de Jonge BL, Kazmierczak KM, Karlowsky JA, Sahm DF (2016) In vitro susceptibility of global surveillance isolates of Pseudomonas aeruginosa to ceftazidime-avibactam (INFORM 2012 to 2014). Antimicrob Agents Chemother 60:4743–4749CrossRef Nichols WW, de Jonge BL, Kazmierczak KM, Karlowsky JA, Sahm DF (2016) In vitro susceptibility of global surveillance isolates of Pseudomonas aeruginosa to ceftazidime-avibactam (INFORM 2012 to 2014). Antimicrob Agents Chemother 60:4743–4749CrossRef
7.
go back to reference Estabrook M, Kazmierczak KM, Wise M, Arhin FF, Stone GG, Sahm DF (2021) Molecular characterization of clinical isolates of Enterobacterales with elevated MIC values for aztreonam-avibactam from the INFORM global surveillance study, 2012–2017. J Glob Antimicrob Resist 24:316–320CrossRef Estabrook M, Kazmierczak KM, Wise M, Arhin FF, Stone GG, Sahm DF (2021) Molecular characterization of clinical isolates of Enterobacterales with elevated MIC values for aztreonam-avibactam from the INFORM global surveillance study, 2012–2017. J Glob Antimicrob Resist 24:316–320CrossRef
8.
go back to reference Bortolaia V, Kaas RS, Ruppe E, Roberts MC, Schwarz S, Cattoir V et al (2020) ResFinder 4.0 for predictions of phenotypes from genotypes. J Antimicrob Chemother 75:3491–500CrossRef Bortolaia V, Kaas RS, Ruppe E, Roberts MC, Schwarz S, Cattoir V et al (2020) ResFinder 4.0 for predictions of phenotypes from genotypes. J Antimicrob Chemother 75:3491–500CrossRef
9.
go back to reference Adámková V, Mareković I, Szabó J, Pojnar L, Billová S, Horvat Herceg S et al (2022) Antimicrobial activity of ceftazidime-avibactam and comparators against Pseudomonas aeruginosa and Enterobacterales collected in Croatia, Czech Republic, Hungary, Poland, Latvia and Lithuania: ATLAS Surveillance Program, 2019. Eur J. Clin Microbiol Infect Dis : Off Publ Eur Soc Clin Microbiol 41:989–996CrossRef Adámková V, Mareković I, Szabó J, Pojnar L, Billová S, Horvat Herceg S et al (2022) Antimicrobial activity of ceftazidime-avibactam and comparators against Pseudomonas aeruginosa and Enterobacterales collected in Croatia, Czech Republic, Hungary, Poland, Latvia and Lithuania: ATLAS Surveillance Program, 2019. Eur J. Clin Microbiol Infect Dis : Off Publ Eur Soc Clin Microbiol 41:989–996CrossRef
10.
go back to reference Zalas-Więcek P, Prażyńska M, Pojnar Ł, Pałka A, Żabicka D, Orczykowska-Kotyna M et al (2022) Ceftazidime/avibactam and other commonly used antibiotics activity against Enterobacterales and Pseudomonas aeruginosa isolated in Poland in 2015–2019. Infect Drug Resist 15:1289–1304CrossRef Zalas-Więcek P, Prażyńska M, Pojnar Ł, Pałka A, Żabicka D, Orczykowska-Kotyna M et al (2022) Ceftazidime/avibactam and other commonly used antibiotics activity against Enterobacterales and Pseudomonas aeruginosa isolated in Poland in 2015–2019. Infect Drug Resist 15:1289–1304CrossRef
Metadata
Title
Activity of ceftolozane/tazobactam and imipenem/relebactam against clinical gram-negative isolates from Czech Republic, Hungary, and Poland—SMART 2017–2020
Authors
Sibylle H. Lob
Stephen P. Hawser
Fakhar Siddiqui
Irina Alekseeva
C. Andrew DeRyke
Katherine Young
Mary R. Motyl
Daniel F. Sahm
Publication date
21-01-2023
Publisher
Springer Berlin Heidelberg
Published in
European Journal of Clinical Microbiology & Infectious Diseases / Issue 3/2023
Print ISSN: 0934-9723
Electronic ISSN: 1435-4373
DOI
https://doi.org/10.1007/s10096-023-04549-1

Other articles of this Issue 3/2023

European Journal of Clinical Microbiology & Infectious Diseases 3/2023 Go to the issue
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine
Webinar | 06-02-2024 | 20:00 (CET)

Mastering chronic pancreatitis pain: A multidisciplinary approach and practical solutions

Severe pain is the most common symptom of chronic pancreatitis. In this webinar, experts share the latest insights in pain management for chronic pancreatitis patients. Experts from a range of disciplines discuss pertinent cases and provide practical suggestions for use within clinical practice.

Sponsored by: Viatris

Developed by: Springer Healthcare